RU98117389A - CONDENSED PYRROLO (2,3-C) CARBAZOLE-6-ONES THAT ENHANCE THE INTERFERON GAMMA ACTIVITY - Google Patents
CONDENSED PYRROLO (2,3-C) CARBAZOLE-6-ONES THAT ENHANCE THE INTERFERON GAMMA ACTIVITYInfo
- Publication number
- RU98117389A RU98117389A RU98117389/04A RU98117389A RU98117389A RU 98117389 A RU98117389 A RU 98117389A RU 98117389/04 A RU98117389/04 A RU 98117389/04A RU 98117389 A RU98117389 A RU 98117389A RU 98117389 A RU98117389 A RU 98117389A
- Authority
- RU
- Russia
- Prior art keywords
- group
- carbon
- alkyl
- carbons
- compound according
- Prior art date
Links
- 102000008070 Interferon-gamma Human genes 0.000 title 1
- 108010074328 Interferon-gamma Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002708 enhancing Effects 0.000 title 1
- 229960003130 interferon gamma Drugs 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 claims 40
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- PIGFYZPCRLYGLF-UHFFFAOYSA-N aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 150000002772 monosaccharides Chemical class 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 1
- VHLKRJCSUDZZTF-UHFFFAOYSA-N carbazol-3-one Chemical compound C1=CC=C2C3=CC(=O)C=CC3=NC2=C1 VHLKRJCSUDZZTF-UHFFFAOYSA-N 0.000 claims 1
- -1 carbon monosaccharide Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000001326 naphthylalkyl group Chemical group 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Claims (16)
где а) R1 выбран из группы, состоящей из Н, алкила с 1-4 углеродами, замещенного или незамещенного арила, арилалкила, гетероарила, гетероарилалкила; C(= O)R9, где R9 представляет алкил с 1-4 углеродами или арил; (CH2)nOR9, где n представляет целое число 1-4; OR10, где R10 представляет Н или алкил с 1-4 углеродами; (CH2)nOR14, где R14 представляет остаток аминокислоты после удаления гидроксильной группы карбоксильной группы; OR14, NR7R8; (CH2)nNR7R8 и O(CH2)nNR7R8; и либо (1) R7 и R8, независимо, представляют Н или алкил с 1-4 углеродами; или (2) R7 и R8 соединены вместе с образованием связывающей группы общей формулы -(CH2)2-Х1-(CH2)2-, где Х1 представляет О, S или CH2; b) R2 выбран из группы, состоящей из Н, SO2R9, СО2R9, C(=O)R9, алкила с 1-8 углеродами, алкенила с 1-8 углеродами, алкинила с 1-8 углеродами и моносахарида с 5-7 углеродами, в котором каждая гидроксильная группа указанного моносахарида независимо выбрана из группы, состоящей из незамещенного гидроксила и фрагмента, заменяющего указанную гидроксильную группу, выбранного из Н, алкила с 1-4 углеродами, алкилкарбонилокси с 2-5 углеродами и алкокси с 1-4 углеродами; где либо 1) каждый алкил с 1-8 углеродами, алкенил с 1-8 углеродами или алкинил с 1-8 углеродами является незамещенным; либо 2) каждый алкил с 1-8 углеродами, алкенил с 1-8 углеродами или алкинил с 1-8 углеродами, независимо, замещен 1-3 группами, выбранными из группы, состоящей из арила с 6-10 углеродами, гетероарила, F, CL, Br, I, CN, NO2, ОН, OR9, O(CH2)nNR7R8, OCOR9, OCONHR9, О-тетрагидропиранила, NH2, NR7R8, NR10CO2R9; NR10CONR7R8, NHC(= NH)NH2, NR10SO2R9; S(O)yR11, где R11 представляет H, алкил с 1-4 углеродами, арил с 6-10 углеродами, или гетероарил; и у равен 1 или 2; SR11, CO2R9, CONR7R8, СНО, COR9, CH2OR7, CH2OR9 CH=NNR11R12, CH=NOR11, CH=NR9 CH=NNHCH(N=NH)NH2; SO2NR12R13, где либо (1a) R12 и R13, независимо, представляют H, алкил с 1-4 углеродами, арил с 6-10 углеродами или гетероарил; либо (2а) R12 и R13 соединены вместе с образованием -(CH2)2-Х1-(CH2)2 связывающей группы; PO(OR11)2, NHR14, НR10R14 ,ОR14 и моносахарида с 5-7 углеродами, в котором каждая гидроксильная группа указанного моносахарида независимо выбрана из группы, состоящей из незамещенного гидроксила и фрагмента, заменяющего указанную гидроксильную группу, выбранного из H, алкила с 1-4 углеродами, алкилкарбонилокси с 2-5 углеродами и алкокси с 1-4 углеродами; с) каждый R3 и R4, независимо, выбран из группы, состоящей из Н, арила с 6-10 углеродами, гетероарила, F, Cl, Br, I, CN, СF3, NO2, ОН, OR9, O(CH2)nNR7R8, OCOR9, OCONHR9 NH2, (CH2)nOR10, (CH2)nOR14,
OR14, NHR14, NR7R8 NR7(CH2)nNR7R8, NR10COR9, NR10CONR7R8, SR11, S(O)yR11,
CO2R9, COR9, CONR7R8, CHO, CH= NOR11, CH=NR9, CH=NNR11R12, (CH2)nSR9, (CH2)nS(O)yR9; CH2SR15, где R15 представляет алкил с 1-4 углеродами; CH2S(O)yR14, (CH2)nNR7R8, (CH2)nNHR14, алкила с 1-8 углеродами, алкенила с 1-8 углеродами и алкинила с 1-8 углеродами; и либо 1) каждый алкил с 1-8 углеродами, алкенил с 1-8 углеродами или алкинил с 1-8 углеродами является незамещенным, либо 2) каждый алкил с 1-8 углеродами, алкенил с 1-8 углеродами или алкинил с 1-8 углеродами является независимо замещенным, как описано выше в b)2); d) R5 выбран из группы, состоящей из алкила с 1-8 углеродами, алкенила с 1-8 углеродами и алкинила с 1-8 углеродами; и либо 1) каждая алкильная, алкенильная или алкинильная группа является незамещенной; или 2) каждая алкильная, алкенильная или алкинильная группа является замещенной 1-3 группами, выбранными из группы, состоящей из F, Cl, Br, I, CN, СF3, NO2, ОН, OR9, O(CH2)nNR7R8, OCOR9, OCONHR9 NH2, (CH2)nOR9, (CH2)nOR14, NR7R8, NR7(CH2)nNR7R8, NR10COR9, NR10CONR7R8, SR11, S(O)yR11, CO2R9, COR9, CONR7R8, CHO, CH=NOR11,CH=NR9, CH=NNR11R12, (CH2)nSR9, (CH2)nS(O)yR9 CH2SR15, CH2S(O)yR14, (CH2)nNR7R8 и (CH2)nNHR14; e) X выбран из группы, состоящей из -N-, -О-, -S-, -S(=O)-, -S(=O)2-, алкилена с 1-3 углеродами, -С(= O)-, -C(R2)=C(R2)-, -C(R2)2-, -CH=CH-, -CH(OH)-CH(OH)-, -C(=NOR11)-, -C(OR11)(R11)-, -C(=O)CH(R15)-, -CH(R15)C(=O)-, -CH2-Z-, -Z-CH2-, -CH2ZCH2-, где Z выбран из группы, состоящей из -C(OR11)(R11)-, О, S, С(=O) и NR11; и алкилена с 1-3 углеродами, замещенного группой, выбранной из группы, состоящей из одной R5 группы-заместителя, SR10, OR10, OR14, R15, фенила, нафтила и арилалкила с 7-14 углеродами.1. Condensed pyrrolo [2,3-c] carbazol-6-one represented by the formula selected from the group consisting of:
where a) R 1 is selected from the group consisting of H, alkyl with 1-4 carbons, substituted or unsubstituted aryl, arylalkyl, heteroaryl, heteroarylalkyl; C (= O) R 9 , where R 9 represents alkyl with 1-4 carbon or aryl; (CH 2 ) n OR 9 where n represents an integer of 1-4; OR 10 where R 10 represents H or alkyl with 1-4 carbons; (CH 2 ) n OR 14 , where R 14 represents the amino acid residue after removal of the hydroxyl group of the carboxyl group; OR 14 , NR 7 R 8 ; (CH 2 ) n NR 7 R 8; and O (CH 2 ) n NR 7 R 8 ; and either (1) R 7 and R 8 independently represent H or alkyl with 1-4 carbons; or (2) R 7 and R 8 are joined together to form a linking group of the general formula - (CH 2 ) 2 —X 1 - (CH 2 ) 2 -, where X 1 is O, S or CH 2 ; b) R 2 is selected from the group consisting of H, SO 2 R 9 , CO 2 R 9 , C (= O) R 9 , alkyl with 1-8 carbon, alkenyl with 1-8 carbon, alkynyl with 1-8 carbon and a 5-7 carbon monosaccharide in which each hydroxyl group of said monosaccharide is independently selected from the group consisting of an unsubstituted hydroxyl and a moiety replacing said hydroxyl group selected from H, alkyl with 1-4 carbon, alkylcarbonyloxy with 2-5 carbon and alkoxy with 1-4 carbons; where either 1) each alkyl with 1-8 carbon, alkenyl with 1-8 carbon or alkynyl with 1-8 carbon is unsubstituted; or 2) each alkyl with 1-8 carbon, alkenyl with 1-8 carbon, or alkynyl with 1-8 carbon, independently, is substituted by 1-3 groups selected from the group consisting of aryl with 6-10 carbon, heteroaryl, F, CL, Br, I, CN, NO 2 , OH, OR 9 , O (CH 2 ) n NR 7 R 8 , OCOR 9 , OCONHR 9 , O-tetrahydropyranyl, NH 2 , NR 7 R 8 , NR 10 CO 2 R 9 ; NR 10 CONR 7 R 8 , NHC (= NH) NH 2 , NR 10 SO 2 R 9 ; S (O) y R 11 , where R 11 is H, alkyl with 1-4 carbon, aryl with 6-10 carbon, or heteroaryl; and y is 1 or 2; SR 11 , CO 2 R 9 , CONR 7 R 8 , CHO, COR 9 , CH 2 OR 7 , CH 2 OR 9 CH = NNR 11 R 12 , CH = NOR 11 , CH = NR 9 CH = NNHCH (N = NH ) NH 2 ; SO 2 NR 12 R 13 , where either (1a) R 12 and R 13 independently represent H, alkyl with 1-4 carbon, aryl with 6-10 carbon or heteroaryl; or (2a) R 12 and R 13 are joined together to form - (CH 2 ) 2 —X 1 - (CH 2 ) 2 linking group; PO (OR 11 ) 2 , NHR 14 , HR 10 R 14 , OR 14 and a monosaccharide with 5-7 carbon, in which each hydroxyl group of the specified monosaccharide is independently selected from the group consisting of unsubstituted hydroxyl and a fragment replacing the specified hydroxyl group selected from H, alkyl with 1-4 carbon, alkylcarbonyloxy with 2-5 carbon and alkoxy with 1-4 carbon; c) each R 3 and R 4 is independently selected from the group consisting of H, aryl with 6-10 carbons, heteroaryl, F, Cl, Br, I, CN, CF 3 , NO 2 , OH, OR 9 , O (CH 2 ) n NR 7 R 8 , OCOR 9 , OCONHR 9 NH 2 , (CH 2 ) n OR 10 , (CH 2 ) n OR 14 ,
OR 14 , NHR 14 , NR 7 R 8 NR 7 (CH 2 ) n NR 7 R 8 , NR 10 COR 9 , NR 10 CONR 7 R 8 , SR 11 , S (O) y R 11 ,
CO 2 R 9 , COR 9 , CONR 7 R 8 , CHO, CH = NOR 11 , CH = NR 9 , CH = NNR 11 R 12 , (CH 2 ) n SR 9 , (CH 2 ) n S (O) y R 9 ; CH 2 SR 15 where R 15 represents alkyl with 1-4 carbon; CH 2 S (O) y R 14 , (CH 2 ) n NR 7 R 8 , (CH 2 ) n NHR 14 , alkyl with 1-8 carbon, alkenyl with 1-8 carbon and alkynyl with 1-8 carbon; and either 1) each alkyl with 1-8 carbon, alkenyl with 1-8 carbon or alkynyl with 1-8 carbon is unsubstituted, or 2) each alkyl with 1-8 carbon, alkenyl with 1-8 carbon or alkynyl with 1- 8 carbon is independently substituted as described above in b) 2); d) R 5 is selected from the group consisting of alkyl with 1-8 carbon, alkenyl with 1-8 carbon and alkynyl with 1-8 carbon; and either 1) each alkyl, alkenyl or alkynyl group is unsubstituted; or 2) each alkyl, alkenyl or alkynyl group is substituted by 1-3 groups selected from the group consisting of F, Cl, Br, I, CN, CF 3 , NO 2 , OH, OR 9 , O (CH 2 ) n NR 7 R 8 , OCOR 9 , OCONHR 9 NH 2 , (CH 2 ) n OR 9 , (CH 2 ) n OR 14 , NR 7 R 8 , NR 7 (CH 2 ) n NR 7 R 8 , NR 10 COR 9 , NR 10 CONR 7 R 8 , SR 11 , S (O) y R 11 , CO 2 R 9 , COR 9 , CONR 7 R 8 , CHO, CH = NOR 11 , CH = NR 9 , CH = NNR 11 R 12 , (CH 2 ) n SR 9 , (CH 2 ) n S (O) y R 9 CH 2 SR 15 , CH 2 S (O) y R 14 , (CH 2 ) n NR 7 R 8 and (CH 2 ) n NHR 14 ; e) X is selected from the group consisting of -N-, -O-, -S-, -S (= O) -, -S (= O) 2 -, alkylene with 1-3 carbons, -C (= O ) -, -C (R 2 ) = C (R 2 ) -, -C (R 2 ) 2 -, -CH = CH-, -CH (OH) -CH (OH) -, -C (= NOR 11 ) -, -C (OR 11 ) (R 11 ) -, -C (= O) CH (R 15 ) -, -CH (R 15 ) C (= O) -, -CH 2 -Z-, -Z -CH 2 -, -CH 2 ZCH 2 -, where Z is selected from the group consisting of -C (OR 11 ) (R 11 ) -, O, S, C (= O) and NR 11 ; and alkylene with 1-3 carbons substituted by a group selected from the group consisting of one R 5 substituent group, SR 10 , OR 10 , OR 14 , R 15 , phenyl, naphthyl and arylalkyl with 7-14 carbons.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/604,474 | 1996-02-21 | ||
US08/604,474 US5616724A (en) | 1996-02-21 | 1996-02-21 | Fused pyrrolo[2,3-c]carbazole-6-ones |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98117389A true RU98117389A (en) | 2000-07-20 |
RU2193037C2 RU2193037C2 (en) | 2002-11-20 |
Family
ID=24419747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98117389/04A RU2193037C2 (en) | 1996-02-21 | 1997-02-20 | Condensed pyrrolo[2,3-c]carbazol-6-ones that enhance activity of gamma-interferon |
Country Status (17)
Country | Link |
---|---|
US (2) | US5616724A (en) |
EP (1) | EP0885229B1 (en) |
JP (1) | JP2000505458A (en) |
KR (1) | KR19990087074A (en) |
CN (1) | CN1098266C (en) |
AT (1) | ATE195124T1 (en) |
AU (1) | AU716265B2 (en) |
BR (1) | BR9707659A (en) |
DE (1) | DE69702705T2 (en) |
DK (1) | DK0885229T3 (en) |
ES (1) | ES2150233T3 (en) |
GR (1) | GR3034533T3 (en) |
HK (1) | HK1017673A1 (en) |
NZ (1) | NZ330837A (en) |
PT (1) | PT885229E (en) |
RU (1) | RU2193037C2 (en) |
WO (1) | WO1997031002A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US7795246B2 (en) * | 1998-08-06 | 2010-09-14 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
ATE361752T1 (en) | 1998-09-25 | 2007-06-15 | Cephalon Inc | METHODS FOR PROPHYLAXIS AND TREATMENT OF DAMAGE TO PERCEPTUAL CURIAL CELLS AND COCHLEAR NEURONS |
US6656474B1 (en) * | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
FR2798931B1 (en) * | 1999-09-22 | 2001-11-16 | Oreal | NOVEL INDOLIC COMPOUNDS, THEIR USE FOR DYEING AND MAKE-UP OF KERATINIC MATERIALS, COMPOSITIONS CONTAINING THEM AND DYEING METHODS |
US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
AR035971A1 (en) * | 2001-05-16 | 2004-07-28 | Cephalon Inc | METHODS FOR THE TREATMENT AND PREVENTION OF PAIN |
ES2500918T3 (en) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Albumin and interferon beta fusion proteins |
US7241779B2 (en) | 2003-12-23 | 2007-07-10 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US7169802B2 (en) | 2003-12-23 | 2007-01-30 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20060293378A1 (en) * | 2005-06-28 | 2006-12-28 | Mcintire Gregory | Method of lowering intraocular pressure |
US20090155352A1 (en) * | 2007-11-20 | 2009-06-18 | Cephalon, Inc. | Microemulsion containing indolocarbazole compound and dosage forms containing the same |
CN103965204B (en) * | 2008-11-19 | 2016-09-07 | 赛福伦公司 | The new model of indazole also [5,4-A] pyrrolo-[3,4-C] carbazole compound |
EP2192121A1 (en) | 2008-11-27 | 2010-06-02 | Cephalon France | Regioselective reduction of fused pyrrolocarbazoles-5,7-diones |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552842A (en) * | 1983-01-28 | 1985-11-12 | Bristol-Myers Company | Process for producing rebeccamycin |
US4923986A (en) * | 1987-03-09 | 1990-05-08 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance K-252 |
DE3835842A1 (en) * | 1988-10-21 | 1990-04-26 | Goedecke Ag | INDOLOCARBAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
DE3833008A1 (en) * | 1988-09-29 | 1990-04-05 | Goedecke Ag | PYRROLOCARBOZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT |
MC2096A1 (en) * | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | SUBSTITUTED PYRROLES |
MX9203409A (en) * | 1989-12-20 | 1992-07-01 | Schering Corp | BCRFI PROTEINS AS INTERFERONE RANGE INHIBITORS. |
DE3942296A1 (en) * | 1989-12-21 | 1991-06-27 | Goedecke Ag | INDOLOCARBAZOL DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF |
US5185260A (en) * | 1991-08-29 | 1993-02-09 | The United States Of America As Represented By The United States Department Of Energy | Method for distinguishing normal and transformed cells using G1 kinase inhibitors |
NZ245203A (en) * | 1991-11-29 | 1997-07-27 | Banyu Pharma Co Ltd | 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates |
US6271242B1 (en) * | 1992-02-10 | 2001-08-07 | Bristol-Myers Squibb Co. | Method for treating cancer using a tyrosine protein kinase inhibitor |
US5405864A (en) * | 1993-10-15 | 1995-04-11 | Syntex (U.S.A.) Inc. | Chemotherapeutic maleimides |
-
1996
- 1996-02-21 US US08/604,474 patent/US5616724A/en not_active Expired - Lifetime
-
1997
- 1997-02-20 DK DK97914792T patent/DK0885229T3/en active
- 1997-02-20 RU RU98117389/04A patent/RU2193037C2/en active
- 1997-02-20 AU AU21914/97A patent/AU716265B2/en not_active Ceased
- 1997-02-20 BR BR9707659A patent/BR9707659A/en not_active Application Discontinuation
- 1997-02-20 EP EP97914792A patent/EP0885229B1/en not_active Expired - Lifetime
- 1997-02-20 AT AT97914792T patent/ATE195124T1/en not_active IP Right Cessation
- 1997-02-20 ES ES97914792T patent/ES2150233T3/en not_active Expired - Lifetime
- 1997-02-20 NZ NZ330837A patent/NZ330837A/en unknown
- 1997-02-20 JP JP9530385A patent/JP2000505458A/en not_active Ceased
- 1997-02-20 WO PCT/US1997/002905 patent/WO1997031002A1/en not_active Application Discontinuation
- 1997-02-20 PT PT97914792T patent/PT885229E/en unknown
- 1997-02-20 CN CN97192377A patent/CN1098266C/en not_active Expired - Fee Related
- 1997-02-20 DE DE69702705T patent/DE69702705T2/en not_active Expired - Fee Related
- 1997-02-20 KR KR1019980706460A patent/KR19990087074A/en active Search and Examination
- 1997-03-28 US US08/827,215 patent/US5801190A/en not_active Expired - Fee Related
-
1999
- 1999-03-24 HK HK99101243A patent/HK1017673A1/en not_active IP Right Cessation
-
2000
- 2000-10-02 GR GR20000402223T patent/GR3034533T3/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU98117389A (en) | CONDENSED PYRROLO (2,3-C) CARBAZOLE-6-ONES THAT ENHANCE THE INTERFERON GAMMA ACTIVITY | |
RU2221798C2 (en) | Imidazonaphthyridines, pharmaceutical composition based on thereof, method for stimulating biosynthesis of cytokine and intermediate compounds | |
RU2327701C2 (en) | Nucleoside derivatives and pharmaceutical composition, with antiviral activity to hcv | |
RU2004106617A (en) | ANTITUMOR ANALOGUES | |
RU2007123235A (en) | ANTITUMOR COMPOUNDS | |
RU2002121628A (en) | Nucleoside compounds and their use | |
RU92004336A (en) | WATER-SOLUBLE DERIVATIVES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING ENZYM TOOPOISOMERS, INTERMEDIATE PRODUCTS | |
RU98108602A (en) | Succinimide and maleimide cytokine inhibitors | |
EP0181110A3 (en) | Histidine derivatives as renin inhibitors | |
RU2004137480A (en) | Hepatitis C Virus Inhibitors | |
RU97112857A (en) | NEW IMMUNOTHERAPEUTIC ARILAMIDES | |
FR2413401A1 (en) | NEW DERIVATIVES OF AMINO SUGARS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
RU2015104031A (en) | SOME AMINOalkylGlucosamine-phosphate derivatives and their use | |
RU2002132897A (en) | PIPERAZINDION COMPOUNDS | |
RU2000128058A (en) | ECTEINASCIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND METHOD FOR TREATING TUMORS | |
RU96121572A (en) | SULPHONIMIDAMIDES, METHOD FOR PRODUCING THEM, PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING IT, METHOD FOR TREATMENT | |
RU2001124604A (en) | Hypertension Medication | |
RU94043771A (en) | Substituted benzimidazole compounds, treatment method, pharmaceutical composition and method of synthesis of benzimidazole compounds | |
EA199900135A1 (en) | DERIVATIVES OF PYRAZOLOPIRIDINE AND THEIR APPLICATION AS A PHARMACEUTICAL PREPARATION | |
RU2001102399A (en) | NEW ASPARTICO DIPEPTIDE ETHER DERIVATIVES AND SWEETENERS | |
RU2006146204A (en) | 3-D-Ribofuranosylthiazole [4, 5-D] Pyrimidine Nucleosides and Their Applications | |
FR2583754B1 (en) | MOLECULAR COMPLEXES FORMED FROM A BENZOFURAN DERIVATIVE AND ALUMINUM CHLORIDE, THEIR PREPARATION AND THEIR USE | |
RU2001110082A (en) | FC RECEPTOR MODULATORS AND THEIR APPLICATION | |
RU94011565A (en) | THIOXANTENONE COMPOUNDS, THEIR USE, ANTI-SMALL COMPOSITION | |
RU2006130865A (en) | Pyrrolopyrimidine derivatives used for the treatment of proliferative diseases |